Behring Diagnostics GmbH announces new structure of its global diagnostics business.
Behring Diagnostics GmbH will be the shareholder of the company's existing and to be established diagnostics companies throughout the world.
The Board of Management, designated by the Hoechst Board of Management, for Behring Diagnostics GmbH includes: Uwe Bicker, MD, PhD, chairman; Friedhelm Blobel, PhD, chief technology officer and head of the global Product Supply Organization (PSO); and Reiner Gleiss, who has been appointed chief financial and administrative officer. Mr. Gleiss has held various positions within the Hoechst organization.
"Our strengthened position within the Hoechst Group provides us an opportunity to better manage our global business while remaining focused on the needs of our customers, and the breadth of our product offering," stated Uwe Bicker, MD, PhD, chairman of Behring Diagnostics GmbH. "We will continue to concentrate on developing new ways to streamline and strengthen our business as we embark on a new era as a leader in global diagnostics."
Reporting to the Chairman, Uwe Bicker, are: Sue Andrews, head of global marketing and head of Europe region I; Charlotte Dexter, corporate communications officer; Heinz Heuser, head of Europe region II; Norbert Madry, PhD, strategy and business process development; John Sullivan, president and CEO of Behring Diagnostics Inc. and head of worldwide business development, and acting head of the Americas region; and Bob Wolf, head of the Asia-Pacific/Middle East region.
Reporting to Friedhelm Blobel are heads of the business lines and global functions of the PSO including: Harmut Hampl, PhD, microbiology; Werner Hampl, OPUS(R); David Kuhn, Emit(R); Erwin Metzmann, PhD, plasma proteins; Hermann Pelzer, PhD, coagulation; Steve Abbott, PhD, global quality systems; Hans-Joachim Fink, PhD, instrumentation; Rita Hofberg, technical product management; Yorck Koehn, logistics; Jerry Rosenstock, Esq., in the United States, patents and licensing; Ted Ullman, PhD, acting head of research; and Guenther Veith, site management Marburg.
Reporting to the Chief Financial and Administrative Officer, Reiner Gleiss, will be the functions of: finance, controlling, treasury, human resources, legal and administration. The positions and reporting lines will be announced during the first quarter of 1997.
Behring Diagnostics GmbH, the in vitro diagnostics company of the Hoechst Group, is one of the four life sciences businesses of the Hoechst Group. Hoechst Marion Roussel, Behring Diagnostics, Hoechst Roussel Vet, and AgrEvo make up the life sciences business of the Hoechst Group.
With headquarters in Frankfurt, Germany, Behring Diagnostics GmbH, manufactures and markets in vitro diagnostic systems used by healthcare professionals in hospitals and laboratories throughout the world. The company has five business lines: plasma proteins, coagulation and microbiology, based in Marburg, Germany; the OPUS(R) business line, located in Westwood, Massachusetts; and the Syva(R) business line, based in San Jose, California. Behring Diagnostics acquired the former Syva Company in 1995. Behring Diagnostics had consolidated net sales of DM 1.027 billion, in 1995, and employs approximately 3,000 worldwide.
OPUS, Syva and Emit are registered trademarks of Behring Diagnostics GmbH.
CONTACT: Behring Diagnostics, Frankfurt
Charlotte Dexter, +44 (171) 384-3390 or
+1 (800) 223-7982, box 9778
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 13, 1997|
|Previous Article:||FIRSTPLUS FINANCIAL announces major marketing campaign with Turner Broadcasting.|
|Next Article:||BNN Corp. reports preliminary record earnings for the quarter and year ended Dec. 31, 1996.|